This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
Rebecca Lumley
21 Apr 2022

PharmaNutra announces new technology to combat iron deficiency

This oral solution allows for high iron absorption while minimising digestive issues 

PharmaNutra has announced a new oral technology designed to increase iron levels in people who are deficient, with fewer side effects than its market rivals.  

Sucrosomial® iron is an innovative design in which ferric pyrophosphate (trivalent iron) is transported within a matrix of phospholipids and sucrose esters of fatty acids. This structure, called Sucrosome®, allows high absorption of iron and is well-tolerated by the gastrointestinal tract.  

Iron is an essential element for the body. It promotes the formation of hemoglobin and myoglobin, supports the immune system and normal cognitive function, as well as supporting growth in children and adolescents.   

There are several reasons an iron deficiency can occur, and it is essential to restore iron levels in the body for normal physiological functioning.  

However, many existing iron supplements have limitations – on one hand due to the side effects associated with iron intake and on the other, the natural difficulty the body has absorbing it.  

Sucrosomial® technology allows iron to be absorbed by the intestinal tract and distributed to the target tissues. Its efficacy has been confirmed by several scientific studies, which observed Sucrosomial® supplementation in many clinical settings where the deficiency of iron was frequent.  

PharmaNutra says Sucrosomial® iron prevents side effects commonly associated with intake of this mineral, such as metallic and unpleasant aftertaste, irritation of the gastric mucosa, nausea or constipation. It can be taken at any time of the day, with or without food, and for long periods of time.  

Meet PharmaNutra at CPHI North America (STAND n.929, FDF sect.) on May 17-19 

Mentioned Companies
Pharmanutra SpA
View company profile
Rebecca Lumley
Digital Editor - Pharma

Related News